This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Exonate receives regulatory approval to start Phase I Clinical Trials in Australia

Posted on 15 Oct 2020

Exonate receives regulatory approval to start Phase I Clinical Trials in Australia

Cambridge - October 2020, Exonate have received a Clinical Trials Notification from the TGA in Australia allowing the Phase Ib/II Clinical Trials to start with its small molecule compound, EXN 407. The study will take place at nine retinal centres throughout Australia recruiting patient volunteers with centre-involved diabetic macular oedema (CI-DMO). Screening is currently ongoing with first dose administration due in late-October. EXN 407 has demonstrated positive pre-clinical results in vivo models of neovascularization without any significant tolerability or safety issues.

Australia has managed the COVID-19 pandemic such that no major delays are expected in patient recruitment.

Dr Catherine Beech, Chief Executive Officer, Exonate said “I am very excited that EXN407 has reached this stage of development. This is a real opportunity to create a drug that will profoundly improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss.”


About Exonate:

Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older.  The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants.


Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing.  These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD.  Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics.

During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. 

Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies.

About Diabetic Macular Oedema (DMO)*:

DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease.

About wet Age-Related Macular Degeneration (wet AMD):

Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset.


The main currently available treatment options for DMO and wet AMD are:

•          anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew.

•          Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss.

•          With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO.







Categories related to this article

Company news